Amgen vs Neurocrine Biosciences: revenue, profit, margins and growth compared
Amgen brought in $36.8B of revenue in fiscal 2025, Neurocrine Biosciences $2.9B in fiscal 2025. Revenue changed by +10.0% at Amgen and +21.4% at Neurocrine Biosciences on the year before, so Neurocrine Biosciences grew faster. Amgen kept 21.0% of its revenue as net profit, Neurocrine Biosciences 16.7%. Free cash flow was $8.1B at Amgen and $748.7M at Neurocrine Biosciences.
Fiscal years as each company reports them; the two may end in different months.
Questions about Amgen and Neurocrine Biosciences
Which is bigger by revenue, Amgen or Neurocrine Biosciences?
Amgen is bigger by revenue: $36.8B in fiscal 2025, against $2.9B for Neurocrine Biosciences in fiscal 2025.
Which keeps more of its revenue as profit, Amgen or Neurocrine Biosciences?
Amgen had a net margin of 21.0% in fiscal 2025; Neurocrine Biosciences had 16.7% in fiscal 2025.
Which grew revenue faster, Amgen or Neurocrine Biosciences?
In their latest fiscal years revenue changed by +10.0% at Amgen and +21.4% at Neurocrine Biosciences.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.